OPCH Stock - Option Care Health, Inc.
Unlock GoAI Insights for OPCH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.00B | $4.30B | $3.94B | $3.44B | $3.03B |
| Gross Profit | $1.01B | $981.22M | $866.92M | $779.61M | $682.26M |
| Gross Margin | 20.3% | 22.8% | 22.0% | 22.7% | 22.5% |
| Operating Income | $321.83M | $314.60M | $240.23M | $190.84M | $110.75M |
| Net Income | $211.82M | $267.09M | $150.56M | $139.90M | $-8,076,000 |
| Net Margin | 4.2% | 6.2% | 3.8% | 4.1% | -0.3% |
| EPS | $1.23 | $1.49 | $0.83 | $0.78 | $-0.04 |
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | Stephens | Initiation | Overweight | $40 |
| October 2nd 2025 | TD Cowen | Initiation | Hold | $30 |
| April 30th 2025 | UBS | Upgrade | Buy | $40 |
| January 23rd 2025 | Jefferies | Upgrade | Buy | $35← $26 |
| January 13th 2025 | BofA Securities | Upgrade | Buy | $33← $26 |
| December 5th 2024 | UBS | Initiation | Neutral | $26 |
| November 4th 2024 | Goldman | Downgrade | Neutral | $27 |
| October 31st 2024 | Jefferies | Downgrade | Hold | $26← $38 |
| October 30th 2024 | BofA Securities | Downgrade | Neutral | $29← $43 |
| July 16th 2024 | JMP Securities | Initiation | Mkt Outperform | $36 |
| February 27th 2023 | Jefferies | Resumed | Buy | $38 |
Earnings History & Surprises
OPCHEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 25, 2026 | $0.46 | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.43 | $0.45 | +4.7% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $0.40 | $0.41 | +2.5% | ✓ BEAT |
Q2 2025 | Apr 29, 2025 | $0.36 | $0.40 | +11.1% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $0.33 | $0.35 | +6.1% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $0.31 | $0.31 | 0.0% | = MET |
Q3 2024 | Jul 31, 2024 | $0.27 | $0.30 | +11.1% | ✓ BEAT |
Q2 2024 | Apr 23, 2024 | $0.23 | $0.26 | +13.0% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $0.29 | $0.32 | +10.3% | ✓ BEAT |
Q4 2023 | Oct 25, 2023 | $0.28 | $0.31 | +10.7% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $0.22 | $0.63 | +186.4% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $0.18 | $0.21 | +16.7% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $0.22 | $0.22 | 0.0% | = MET |
Q4 2022 | Oct 27, 2022 | $0.21 | $0.21 | 0.0% | = MET |
Q3 2022 | Jul 27, 2022 | $0.22 | $0.19 | -13.6% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $0.13 | $0.17 | +30.8% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $0.24 | $0.24 | 0.0% | = MET |
Q4 2021 | Nov 4, 2021 | $0.19 | $0.20 | +5.3% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $0.09 | $0.18 | +100.0% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $-0.01 | $-0.02 | -199.9% | ✗ MISS |
Latest News
Stephens & Co. Initiates Coverage On Option Care Health with Overweight Rating, Announces Price Target of $40
📈 PositiveB of A Securities Maintains Buy on Option Care Health, Raises Price Target to $35
📈 PositiveDeutsche Bank Maintains Buy on Option Care Health, Raises Price Target to $36
📈 PositiveTD Cowen Maintains Hold on Option Care Health, Lowers Price Target to $27
📉 NegativeCitizens Maintains Market Outperform on Option Care Health, Lowers Price Target to $36
➖ NeutralBarrington Research Maintains Outperform on Option Care Health, Maintains $38 Price Target
📈 PositiveOption Care Health shares are trading lower. The company reported Q3 financial results.
📉 NegativeOption Care Health Raises FY2025 Adj EPS Guidance from $1.65-$1.72 to $1.68-$1.72 vs $1.71 Est; Raises FY2025 Sales Guidance from $5.500B-$5.650B to $5.600B-$5.650B vs $5.626B Est
📈 PositiveOption Care Health Q3 2025 Adj. EPS $0.45 Beats $0.43 Estimate, Sales $1.435B Beat $1.413B Estimate
📈 PositiveMorgan Stanley Initiates Coverage On Option Care Health with Overweight Rating, Announces Price Target of $35
📈 PositiveTD Cowen Initiates Coverage On Option Care Health with Hold Rating, Announces Price Target of $30
➖ NeutralBarrington Research Maintains Outperform on Option Care Health, Maintains $38 Price Target
📈 PositiveOption Care Health Appoints Meenal Sethna As Executive Vice President And CFO, Effective October 1, 2025; Succeeds Mike Shapiro
➖ NeutralFrequently Asked Questions about OPCH
What is OPCH's current stock price?
What is the analyst price target for OPCH?
What sector is Option Care Health, Inc. in?
What is OPCH's market cap?
Does OPCH pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OPCH for comparison